Effect of recombinant tumor necrosis factor on HL‐60 cells: Cell‐cycle specificity and synergism with actinomycin D Journal Article


Authors: Darzynkiewicz, Z.; Carter, S. P.; Old, L. J.
Article Title: Effect of recombinant tumor necrosis factor on HL‐60 cells: Cell‐cycle specificity and synergism with actinomycin D
Abstract: The tumor necrosis factor (TNF) exhibits a multitude of activities depending on the type of target cells. We characterized the cytostatic and cytotoxic effects of recombinant TNF, alone and in combination with actinomycin D (AMD), on the human leukemic cell line HL‐60. Because HL‐60 cells, when triggered to monocytic differentiation by phorbol esters, are known to produce and secrete TNF, their sensitivity to the factor could indicate an autocrine function of TNF in this cell system. Indeed, HL‐60 cells were affected by TNF; their doubling time was increased by about 50% and progression through the cell cycle was perturbed. Initially, (up to 8 h) TNF induced a temporary arrest in G2 while later (24–48 h) it delayed progression through the G1 phase. Also, a transient increase in RNA content peaking at 6–8 h was apparent. The cytotoxicity of TNF alone was low. Thus, TNF may be involved in the regulation of the cell cycle of HL‐60 cells during early stages of their differentiation. The cytotoxicity of TNF was markedly potentiated in the presence of AMD; the effect was AMD but not TNF concentration‐dependent. Whereas at 20 and 50 ng/ml of AMD alone nonviable cells did not exceed 20% during the first 24 h of treatment, their proportion increased to 80 and 90%, respectively, in the presence of TNF. The most sensitive were cells in the S phase of the cell cycle. The observed synergistic effect of TNF and AMD does not appear to be caused by the action of TNF increasing the permeability of the cell membrane to AMD. The results indicate that HL‐60 cells, ordinarily resistant to the cytotoxic action of TNF, can be rendered sensitive by treatment with AMD. This implies that a combination of TNF and AMD may be considered in oncology for treatment of tumors otherwise nonresponding to TNF alone. Copyright © 1987 Wiley‐Liss, Inc.
Keywords: human cell; drug potentiation; cytology; cell survival; cell cycle; cell division; cell line; cytotoxicity; in vitro study; histology; drug synergism; kinetics; recombinant tumor necrosis factor; drug mechanism; recombinant proteins; dactinomycin; drug cytotoxicity; drug sensitivity; glycoproteins; tumor necrosis factor; intoxication; cell strain hl 60; leukemia, myelocytic, acute; human; priority journal; support, u.s. gov't, p.h.s.; blood and hemopoietic system
Journal Title: Journal of Cellular Physiology
Volume: 130
Issue: 3
ISSN: 0021-9541
Publisher: John Wiley & Sons, Inc.  
Date Published: 1987-03-01
Start Page: 328
End Page: 335
Language: English
DOI: 10.1002/jcp.1041300304
PUBMED: 3470296
PROVIDER: scopus
DOI/URL:
Notes: Article -- Export Date: 5 February 2021 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Lloyd J Old
    593 Old